decisionhealth Newsletters, Answer Books - 2008 Issue 5 (May)
National_Coverage_Determinations_Manual / TUMOR_ANTIGEN_BY_IMMUNOASSAY_CA_15
Subscribe or sign in to view the full article.
Article Overview
This policy article is about Medicare coverage guidance for tumor antigen immunoassay testing used in oncology monitoring, with emphasis on breast cancer management and the role of serial testing over time. It is intended for coders, billers, and clinical documentation teams who need to understand the scope of the coverage policy, the circumstances it addresses, and the limitations described in the manual.
Why This Topic Matters
Coverage policies for tumor marker testing affect whether services are considered payable and how documentation should support medical necessity in cancer follow-up and treatment monitoring.
Article Sections
-
Indications
Describes the general clinical contexts addressed by the policy, including monitoring and follow-up considerations for certain malignancies and breast cancer management.
-
Limitations
Summarizes the coverage limitations and the types of patient presentations or uses that fall outside the policy scope.
What You Will Learn
- The general purpose of the coverage policy for tumor antigen immunoassay testing
- The clinical context in which the policy discusses breast cancer monitoring
- The broad limitations on coverage described by the manual
- The role of serial testing within the policy’s scope
Who Should Read This
- Medical coders
- Medical billers
- Oncology documentation specialists
- Compliance staff
- Revenue cycle teams
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com